A neurysm or arterial enlargement is the gross phenotype that manifests progressive organ failure of large arteries, including the aorta. Aortic aneurysm is usually not inherently dangerous, but enlarged arteries show a predisposition for tear (known as dissection), with high mortality rates. Clinicians recognize two predominant spatial distributions of aortic aneurysms in patient groups. The most common form, abdominal aortic aneurysm (AAA), is typically associated with advanced age and atherosclerosis, with attendant risk factors such as hypercholesterolaemia, hypertension and/or diabetes. These lesions are pathologically characterized by atheromata, invasion of inflammatory cells, destructive extracellular matrix remodelling, and depletion and dysfunction of vascular smooth muscle cells (VSMCs). Although it is clear that genetic determinants influence the development of AAA, there has been no description of a single major gene or locus effect that is sufficient to cause isolated abdominal aneurysm (that is, in the absence of evidence for a more systemic vasculopathy). The weight of evidence therefore indicates that AAA is a complex disorder that integrates the influence of predisposing genes with lifestyle-associated risk factors -analogous to coronary artery disease.
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The second common site for aneurysm is the thoracic ascending aorta. Unlike AAA, thoracic aortic aneurysm (TAA) occurs in all age groups, is more highly associated with hereditary influences and does not show obligate association with cardiovascular risk factors. Pathologically, inherited forms of TAA typically show destructive matrix remodelling with elastin fragmentation, proliferation of VSMCs and a less prominent inflammatory component without atheromata. Many presentations of TAA show classic Mendelian inheritance with high or complete penetrance, suggesting the major contribution of a single gene. Familial TAA can be subdivided into syndromic presentations that show prominent features of a systemic connective tissue disorder (such as Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS)) and nonsyndromic presentations (such as bicommissural aortic valve with TAA, and isolated familial TAA). Both the syndromic and non-syndromic groups include many disorders in which disease predominates in the very proximal ascending thoracic aorta (Fig. 1 ). In fact, there are only rare exceptions in which the ascending aorta is infrequently involved -such as vascular Ehlers-Danlos syndrome. Table 1 includes a list of human and mouse single-gene disorders associated with aneurysm predisposition.
Over the past couple of decades, the genes responsible for heritable aortic aneurysm have been identified at an accelerating pace. Gene identification has allowed the creation of mouse models of inherited aortic aneurysm, providing the first opportunity to temporally and comprehensively interrogate the pathogenic sequence of aneurysm, extending from predisposition to clinical consequence, in an experimental context that mimics the physiological complexity of the human system. This combination of human molecular genetics and animal modelling has shown the involvement of diverse cytokine pathways, prominently the role of the transforming growth factor-β (TGF-β) pathway in aortic aneurysm. This Review focuses on the mechanisms of failure of large vessel wall homeostasis that challenge or inform historical perspectives, attempts to integrate emerging models of disease, and discusses the remaining challenges and opportunities in aneurysm research.
Excessive focus on elastin in TAA pathogenesis
There has been disproportionate historical focus on elastic fibres in pathogenetic models of inherited TAA. This derives from the nearuniform histological observation of reduced elastin content and elastic fibre fragmentation in the aortic media (the middle aortic layer), known as cystic medial necrosis. However, many elastin-deficiency states do not associate with aneurysm as a prominent phenotype. Although aortic aneurysm is an extremely rare manifestation of cutis laxa syndromes caused by mutations in the elastin gene 1 , it is not observed in mice or humans with dominant and recessive forms of cutis laxa caused by deficiency of fibulin-5 (ref. 2), a crucial mediator of elastogenesis. By contrast, aneurysmal disease, including prominent involvement of the ascending aorta, is highly penetrant in inherited cutis laxa caused by fibulin-4 deficiency 3 . Humans and mice with a fibrillin-1 deficiency show failed elastic fibre homeostasis and highly penetrant aortic root aneurysms in the context of MFS (see ref. 4 and references therein). Pseudoxanthoma elasticum caused by ABCC6 deficiency in humans also shows postnatally acquired elastic fibre fragmentation in the aorta, but does not typically show aneurysm 5 . These observations raise the important question of which molecular events, besides elastin-related issues, are common to the fibrillin-1-and fibulin-4-deficiency states but not recapitulated by fibulin-5 deficiency. The focus on the aortic media and elastic fibres may have been a distraction, and further insight could come from considering other distinguishing features of the proximal ascending aorta, including developmental cellular ontology. Genes mutated in MFS and vascular Ehlers-Danlos syndrome (FBN1 and COL3A1, respectively) encode extracellular matrix elements (fibrillin-1 and collagen α-1(III), respectively). This discovery led to the generation of pathogenetic models that singularly invoke inherent structural weakness of the tissues. Such a view a b boded poorly for the development of productive medical treatment strategies, requiring a means to alter the structural composition of inherently weak tissues. Fortunately, for both patients and researchers, the story of hereditary aneurysm has turned out to be much more complex and potentially permissive for therapeutic intervention.
MFS provides a link between aneurysm and TGF-β
A shift in thinking about the pathogenesis of aortic aneurysm occurred during the study of MFS 4 . Although many of the clinical manifestations of MFS could be caused by simple tissue weakness imposed by fibrillin-1 deficiency (such as aortic aneurysm, eye lens dislocation and emphysema), others were not so easily reconciled (bone overgrowth, craniofacial alterations and myxomatous valve disease). Insight came from studying lung disease in fibrillin-1-deficient mice. Contrary to expectation, mouse models of MFS did not show destructive and inflammatory emphysema. Instead, they showed primary failure of distal alveolar septation during late embryogenesis and the perinatal period 6 . Mechanistic hypotheses built on the observation that fibrillin proteins show marked homology to latent TGF-β-binding proteins (LTBPs). Most TGF-β is secreted from cells in the context of a large latent complex (LLC) that includes the mature cytokine, a dimer of its processed amino-terminal propeptide (latency-associated peptide) and one of three LTBP isoforms (LTBP-1, LTBP-3 or LTBP-4). LTBPs target the TGF-β LLC to binding partners such as fibronectin and microfibrils composed of fibrillin-1 -an event that is thought to regulate TGF-β bioavailability and activity by controlling access to, or the efficiency of, TGF-β activators. One hypothesis was that failed or improper matrix sequestration of the LLC owing to fibrillin-1 deficiency could lead to promiscuous TGF-β activation. In keeping with this concept, the developing lungs of fibrillin-1-deficient mice showed decreased LLC levels but raised levels of free TGF-β and increased TGF-β signalling, as demonstrated by the nuclear translocation and phosphorylation of receptor-activated SMAD proteins 2 and 3 (pSMAD2/3). Notably, distal alveolar septation could be restored in fibrillin-1-deficient mice by the administration of a pan-specific anti-TGF-β neutralizing antibody 6 . Other manifestations of MFS, including myxomatous mitral valve disease, skeletal myopathy and, most importantly, aortic root aneurysm, were associated with increased TGF-β signalling in mouse models of MFS, and were attenuated or prevented by TGF-β antagonism with a neutralizing anti-TGF-β antibody in these mice in vivo 4, 7 .
TGF-β receptor mutations
Perhaps the most direct evidence of a major role for TGF-β in aneurysm pathogenesis came from the finding that mutations in the TGFBR1 and TGFBR2 genes -which encode the TGF-β receptor subunits TGFR-1 (also known as ALK-5) and TGFR-2, respectively -result in aneurysm conditions that have undeniable phenotypic overlap with MFS, a notable example of which is LDS 8, 9 ( Table 1 ). Similar to MFS, patients with LDS typically show skeletal involvement, including long fingers, chest wall deformity and scoliosis. Other shared features include widening of the dural sac, skin stretch marks and mitral valve prolapse. Patients with LDS typically do not show lens dislocation, and can show many discriminating systemic features such as widely spaced eyes (hypertelorism), cleft palate or bifid uvula, cervical spine malformation or instability, osteoporosis and club foot deformity 8, 10 . Most importantly, patients with LDS show highly penetrant arterial tortuosity (an elongation of an artery resulting in a twisted course) and a strong predisposition for aneurysm and dissection throughout the arterial tree. Vascular disease in patients with LDS is more aggressive than in those with MFS, with rupture at a younger age (as young as 6 months) and at smaller aortic dimensions 10 . Nearly all patients with LDS are heterozygous for missense substitutions in the kinase domain of TGFR-1 or TGFR-2. Recombinant expression of mutant receptors in cells naive for the corresponding receptor subunit failed to support TGF-β signalling, leading to the hypothesis that haploinsufficiency was the relevant mechanism 9 .
If this were the case, however, the identification of early nonsense mutations that elicit messenger RNA clearance through nonsensemediated mRNA decay or whole allele deletions might be expected. Instead, the skewed mutational repertoire seems to manifest selection for receptor variants that traffic to the cell surface and bind ligand but lack the ability to propagate signal. Co-transfection studies in human cells using equimolar concentrations of normal and mutant receptors and experiments with heterozygous patient cells have shown apparent preservation of the signalling potential of wild-type receptor subunits, excluding a conventional dominant-negative mechanism 8, 9 . Notably, patient vascular tissue obtained at surgery or autopsy has consistently shown paradoxically enhanced TGF-β signalling, demonstrated by nuclear accumulation of pSMAD2 in VSMCs and increased output of TGF-β-driven gene products such as collagens and connective tissue growth factor (CTGF) 8, 10 . The architectural changes seen in the aortic wall of patients with LDS are highly reminiscent of those seen in MFS and other inherited forms of aortic root aneurysm. The mechanisms underlying this paradoxical effect remain unknown, but potentially include altered receptor trafficking, impaired autoregulation of TGF-β signalling, alternative signalling cascades or non-autonomous cellular events (see 'Cancer biology as a guide to aneurysm'). Heterozygous lossof-function SMAD3 mutations recapitulate both the LDS phenotype and paradoxical enhancement of TGF-β signalling in the aortic wall 11 .
Other TGF-β links to aneurysm
Several other aneurysmal disorders have been linked to TGF-β signalling 4 . High levels of TGF-β signalling, as assessed by nuclear pSMAD2 accumulation, have been observed in surgical samples from patients with diverse aneurysm conditions such as isolated familial TAA and bicommissural aortic valve with TAA 4 . Patients with autosomal recessive arterial tortuosity syndrome show diffuse and severe arterial tortuosity that is often associated with vascular stenoses, segmental vascular hypoplasia and arterial aneurysms, caused by loss-of-function mutations in the SLC2A10 (also known as GLUT10) gene, which encodes the integral membrane protein glucose transporter type 10 (ref. 12) . Vascular tissue from patients with arterial tortuosity syndrome shows the same signature of high TGF-β signalling seen in tissue from patients with MFS or LDS. Although the mechanism is poorly understood, cultured fibroblasts from patients with arterial tortuosity syndrome show impaired expression of the proteoglycan decorin -an antagonist of TGF-β superfamily signalling 12 . Deficiency of the extracellular protein fibulin-4 causes autosomal recessive cutis laxa in association with arterial tortuosity and aortic aneurysm in both humans and mice 3, 13 . Curiously, fibulin-5 deficiency causes cutis laxa with arterial tortuosity but not aneurysm. Both fibulin-4 and fibulin-5 bind to fibrillin-1 and elastin, and deficiency in fibulin-4 or 
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fibulin-5 is associated with profound failure of elastogenesis -the probable cause of arterial tortuosity. Fibulin-5 mainly promotes elastin fibre assembly by the recruitment of tropoelastin to microfibrils 14 . By contrast, fibulin-4 is needed for the recruitment of lysyl oxidase (LOX), a copperdependent enzyme that catalyses crosslinking of elastin molecules 14 . In keeping with these findings, LOX-deficient mice show severely disrupted aortic laminae, arterial tortuosity and low penetrance aneurysm 15 . Mice and humans deficient in fibulin-4 show increased TGF-β signalling in the vessel wall, which may be directly related to the ability of LOX to inhibit TGF-β enzymatically 16 . In this light, it seems that the aneurysm phenotype specific to fibulin-4 deficiency manifests a loss of a function other than elastin crosslinking, plausibly including TGF-β repression.
Despite several lines of evidence invoking high TGF-β signalling in aneurysm, conflicting observations exist. For example, high vascular TGF-β signalling was shown in Emilin1-deficient mice in association with a diffusely small vascular system and hypertension in juvenile animals 17 . The developmental timing and vascular distribution of high TGF-β signalling were not assessed, and there was no comprehensive analysis for aneurysms 17 . Another study has shown that lineage-specific ablation of TGF-β signalling in VSMCs in the ascending aorta results in perturbations of vascular morphogenesis in fetal mice, including persistent truncus arteriosus, impaired elastogenesis and apparent vessel widening that was equated with aneurysm 18 ; similar impairment of elastogenesis was seen only in the descending aorta of mice with global Tgfbr2 deletion in VSMCs
19
. There is further indirect evidence that low TGF-β signalling may also be involved in developmental presentations of aneurysm in MFS. An emerging view is that the fibrillin proteins have a dichotomous role in TGF-β regulation. Fibrillin-2 was shown to concentrate TGF-β ligands (prominently BMP7), and this is required to support morphogenetic events at sites of intended function. In the . Mice deficient in both fibrillin-1 and fibrillin-2 show persistent truncus arteriosus, which historically has been associated with loss of TGF-β signalling (F. Ramirez, personal communication).
Downstream of TGF-β
Little is known about the precise pathogenetic sequence downstream of TGF-β that is involved in aneurysm progression. Enhancement of matrix metalloproteinase (MMP) activity is frequently invoked. Such a model is both theoretically appealing and experimentally validated. Evidence includes high levels of MMP expression and activity in many natural and experimentally induced presentations of aneurysm, and the ability of MMP inhibitors (such as doxycycline) to attenuate aneurysm progression, including in MFS mouse models 21 . Although TGF-β has been associated with reduced expression and activity of several MMPs in many tissues and contexts, it has been shown to specifically induce MMP2 and MMP9 expression -the MMPs that are most closely associated with aneurysm conditions such as MFS 22, 23 . Most studies of TGF-β-related disease states have focused on 'canonical' (SMAD-dependent) signalling cascades, with a more historic than empirical basis for such an emphasis. More recently, it has been shown that ligand-activated TGF-β receptors can stimulate signalling through non-canonical pathways, including the phosphatidylinositol-3-OH kinase (PI(3)K)/AKT cascade, the Rho-associated protein kinase (ROCK) cascade and the mitogen-activated protein kinase (MAPK) cascade 24 (Fig. 2) . Although mouse and human models of MFS demonstrate upregulation of canonical signalling 7 , its importance is not clear. There is emerging evidence that MAPKs may have a role in aneurysm. For example, activation of p38 has been observed in the aorta . We have also observed TGF-β-and angiotensin II type 1 receptor (AT1R)-dependent activation of the extracellular-signal regulated kinases (ERK1 and ERK2) in the aorta of fibrillin-1-deficient mice, and abrogation of pathological aortic root growth after treatment with a specific ERK inhibitor 26, 27 . ERK1 upregulation has also been observed in fibulin-4 deficiency in mice and humans 4, 13 , perhaps providing a link between the loss of function of fibulin-4 and fibrillin-1.
Infusion of angiotensin II (Ang II) or the application of CaCl 2 promotes AAA in mice. Antagonism of c-Jun N-terminal protein kinase 1 (JNK1) signalling has been shown to attenuate disease progression in an AAA mouse model 28 . This occurred in association with reduced MMP2 and MMP9 activity and enhanced LOX expression. ERK activity is known to be instrumental in diverse aspects of vascular pathology, including VSMC proliferation and migration, and has been linked to TGF-β-mediated MMP upregulation and epithelial-tomesenchymal transition. Finally, low penetrance aneurysm has been observed in human conditions known to modify Ras signalling, a major upstream activator of ERK. These include gain-of-function mutations in the PTPN11 gene, which encodes a protein tyrosine phosphatase, leading to Noonan syndrome, and loss-of-function mutations in the NF1 gene, which encodes a Ras GTPase-activating protein, leading to neurofibromatosis type 1 (refs 29, 30) ( Table 1 and Fig. 2 ).
Angiotensin II and aneurysm
Aortic aneurysm and dissection can be modelled through the infusion of Ang II in mice deficient for apolipoprotein E (Apoe −/− ) (ref. 4 and references therein), or with higher doses in aged wild-type mice 31 . Aneurysm formation occurs with high penetrance in the suprarenal abdominal aorta; the ascending aorta can also be involved with lower frequency and severity. Aneurysm has been shown to be independent of hypercholesterolaemia and hypertension in this model, but requires intact AT1R signalling, innate immunity and MMP activity 4 . The increased expression of monocyte chemoattractant protein-1 (MCP-1), its receptor (CCR2) and interleukin-6 (IL-6) have been demonstrated in models of Ang-II-induced aneurysm, and CCR2 signalling has been shown to contribute to IL-6 expression. Ang II infusion in mice was shown to associate with accumulation of CCR2 + macrophages in the vascular adventitia -the outermost vessel tissue layer -specifically at the sites of aneurysm formation and most prominently at the sites of dissection 31 . Mice lacking CCR2 protein showed reduced macrophage accumulation, decreased IL-6 and MCP-1 expression, and protection from dissection in response to Ang II infusion. In vitro modelling has demonstrated that monocytes co-cultured with adventitial fibroblasts upregulate IL-6 and MCP-1, and show enhanced differentiation into macrophages. Although the activity of a fibroblastderived paracrine factor was suggested, there has been no speculation about its identity. The potent anti-inflammatory cytokine TGF-β is a promising candidate. TGF-β is known to induce the expression of both IL-6 and MCP-1 in many cell types, including fibroblasts and VSMCs, and can positively regulate monocyte recruitment and macrophage differentiation 4 . Increased MCP-1 expression was also proposed as a determinant of disease in response to JNK1 signalling, with JNK1 suppressing the expression of LOX that normally negatively regulates MCP-1 (ref. 32). It is notable that although the loss of CCR2 or IL-6 expression prevented early dissection in response to acute Ang II infusion in mice, it did not preclude dissection after chronic infusion. Increased adventitial IL-6 expression was observed in human aneurysms, but only at sites of dissection. In this light, it seems that the described IL-6 and MCP-1 amplification loop contributes to, but is not required for, Ang-IIinduced aneurysm and dissection in mice, and more work needs to be done to determine its contribution to disease pathogenesis in humans.
Attempts to integrate TGF-β signalling into the pathogenesis of Ang-II-induced aneurysm models are frustrated by limited and contradictory empirical knowledge. As previously mentioned, Ang II signalling through AT1R has the capacity to enhance TGF-β signalling by inducing the expression of ligands, receptors and activators. It has also been reported that Ang II can activate the intracellular SMAD signalling cascade in VSMCs, in a TGF-β-independent manner 33 (Fig. 2) . Ang II can also regulate MAPK signalling cascades independently of TGF-β, with the suggestion that signalling through its different receptor subtypes (AT1R and AT2R) can have varying and Table 1 ). MAP3K7, mitogen-activated protein kinase kinase kinase 7 (also known as TAK1); MEK1, MAP kinase kinase 1; MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase; p190 RhoGAP, Rho GTPase-activating protein 5; SHP2, protein tyrosine phosphatase 2C; α-SMA, α-smooth muscle actin. 
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even opposing effects. Conversely, a recent study has shown that the resistance to Ang-II-induced aneurysm in normocholesterolaemic C57BL/6 mice is disrupted by systemic treatment with a neutralizing anti-TGF-β antibody 34 . Again, these lesions were inflammatory in nature, and the incidence of aneurysm and dissection was greatly attenuated after monocyte depletion. These observations indicate that TGF-β may be protective specifically in the setting of acute and intense inflammation. Another study has shown that neutralizing anti-TGF-β antibody provided significant protection from Ang-II-induced inflammatory aneurysms after targeted silencing of CXCL10, a known chemoattractant for monocytes and macrophages 35 . Taken together, these data suggest that TGF-β has biphasic and discordant roles in the pathogenesis of mouse Ang-II-induced aneurysm, and that TGF-β antagonism can be protective in a context-dependent manner.
Smooth muscle cytoskeletal elements and aneurysm
Studies with MFS mouse models have shown that phenotypic changes in aortic VSMCs precede elastolysis and gross medial remodelling 22 . These changes include adoption of a general 'synthetic' (as opposed to 'contractile') character, and morphological changes consistent with cytoskeletal rearrangement. More recent work identifying genes associated with isolated familial TAA has directly implicated perturbation of the contractile apparatus in the pathogenesis of aneurysm. Heterozygous mutations in MYH11, which encodes smooth muscle myosin heavy chain 11 (MYH11), cause non-syndromic ascending aortic aneurysm in association with patent ductus arteriosus and rare incidence of bicuspid aortic valve 36, 37 . By contrast, heterozygous mutations in ACTA2, which encodes α-smooth muscle actin (α-SMA), cause a vascular disorder involving high, but incomplete, penetrance of ascending aortic aneurysm and dissection, with a lower incidence of descending aortic aneurysm and dissection, patent ductus arteriosus and bicuspid aortic valve 38 . Many patients show a purplish discoloration of the skin in a network pattern, caused by altered tone in deep dermal capillaries (livedo reticularis) and pigmented cysts of the iris (iris flocculi). VSMCs isolated from patients with MYH11 mutations showed high proliferative rates, and upregulation of insulin-like growth factor 1 (IGF-1) signalling 37 and components of the Ang II signalling cascade. Although it has been reported that isolated patient cells do not show evidence of increased TGF-β signalling, the data and experimental conditions were not reported. This is particularly important, because the high TGF-β signalling seen in the aorta of humans and/or mice with MFS or LDS is not recapitulated in cultured VSMCs, suggesting the necessity of tissue-specified contexts. More recently, a study found that aortic tissue from a patient with MYH11 mutations showed high VSMC expression of the calcium-binding protein S100A12, an event previously linked to high TGF-β expression and signalling in mice 39 . In addition to MYH11 and α-SMA, a third cytoskeletal (but noncontractile) protein has been implicated in aortic aneurysm. The large actin-binding protein filamin-A shows altered expression or function in the neurological condition periventricular nodular heterotopia 40 .
Encoded by the FLNA gene, on the X chromosome, filamin-A has a diverse repertoire of binding partners, making the delineation of a specific causal pathway difficult. Moreover, only a small subset of filamin-A-deficient women have been reported to show a predisposition . The force generated by cellular contraction against a resistance imposed by the neighbouring matrix has been shown to contribute positively to TGF-β activation in an integrin-dependent manner 43 . Acute disruption of the actin cytoskeleton in human mesangial cells using cytochalasin D, for example, has been shown to reduce SMAD2 phosphorylation and TGF-β-induced collagen α-1(I) (but not α-1(IV)) expression 44 . Other studies have shown that cytoskeletal disruption can induce the expression of TGF-β-driven gene products, such as plasminogen activator inhibitor-1 (PAI-1) and connective tissue growth factor, in VSMCs independently of TGF-β ligand or receptor, and that these effects are at least partly mediated by activation of the ROCK and/or MAPK signalling cascades 45 . It remains impossible to determine the chronic consequences of such manipulations in the context of a healthy or diseased tissue.
Prospects for aneurysm treatment
Standard medical therapy for aortic aneurysm has revolved around blood pressure control to limit aortic wall stress. The implication of TGF-β signalling in the pathogenesis of aortic aneurysm suggested an opportunity for more specific therapy. Blockade of Ang II signalling through AT1R had previously been shown to limit TGF-β signalling and fibrosis in rodent models of chronic kidney disease. Indeed, in a mouse model of MFS, the AT1R blocker losartan prevented progressive aortic aneurysm 7 . Potential mechanisms for aneurysm treatment include the prevention of AT1R-induced expression of TGF-β ligands, receptors and activators such as thrombospondin-1 (TSP-1) or MMPs. Prenatal initiation of losartan treatment in MFS mouse models resulted in full normalization of aortic root size, aortic root growth rate and aortic wall architecture. Importantly, postnatal initiation of therapy in the context of established aneurysmal dilatation and medial degeneration also achieved full suppression of aortic root growth and productive remodelling of the aortic wall, with decreased elastin fragmentation and matrix deposition. Several observations pointed to TGF-β antagonism as the relevant mechanism. First, the protection achieved by losartan correlated with reduced nuclear accumulation of pSMAD2 and reduced expression of TGF-β-driven gene products such as PAI-1 and CTGF. Second, other agents with comparable blood-pressure-lowering effects that did not alter TGF-β signalling were associated with a small decline in aortic root growth rates compared with losartan, and had no effect on aortic wall architecture. Third, losartan limited the growth of the aortic root, which showed pathological dilatation and increased TGF-β signalling, but had no effect on the growth of other aortic segments, which showed neither. Losartan also limited aortic root growth in a subset of children with severe and rapidly progressive MFS 46 . Several large and randomized clinical trials of losartan in MFS are under way 47 .
Embracing paradox
Despite recent advances in understanding aneurysm pathogenesis, many paradoxes remain to be reconciled. For example, it is not clear why defects in structural or regulatory matrix elements, signalling molecules or contractile proteins culminate in focal aneurysms rather than a diffusely fragile and dilated arterial tree. If haemodynamic stress is the answer, it remains unclear why lesions occur on both the high-and low-pressure (that is, the root of the pulmonary artery) sides of the circulation. Another paradox is why conditions such as MFS and LDS show a high predisposition for focal aneurysm and primary dissection in the periductal region of the proximal descending thoracic aorta. In such conditions, it is not known why therapies aimed at blunting TGF-β signalling at the level of ligand bioavailability (such as a neutralizing anti-TGF-β antibody or losartan) or events far downstream of TGF-β (such as MMP inhibition with doxycycline) make things better, whereas events or manipulations that target the intracellular signalling cascade (such as TGFBR1 or TGFBR2 mutations in LDS, or the introduction of SMAD4 haploinsufficiency in fibrillin-1-deficient mice 26, 27 ) routinely make things worse. The paradoxical increase in TGF-β signalling observed in patients with LDS could be explained if receptor-mediated activation of the canonical and non-canonical cascades relies on separable activities of the receptor complex. It has been suggested that distinct kinase activities underlie the phosphorylation of SMAD proteins and the ShcA adaptor protein -the proximal events in the ERK cascade 48 . Furthermore, TGF-β-mediated activation of other MAPKs has been linked to receptor-mediated ubiquitylation of the TRAF6 ubiquitin ligase 49 (Fig. 2) . If abnormal receptor complexes in LDS have relative preservation of non-canonical signalling but feedback regulation is disproportionately governed by canonical signalling, then compensatory mechanisms, such as increased ligand expression and/or activation, would drive excessive non-canonical TGF-β signalling in a cell-autonomous manner (Fig. 3a) .
Cancer biology as a guide to aneurysm
In many respects, there are intriguing parallels to be drawn with the TGF-β cancer paradox. TGF-β can function as a tumour suppressor, with prominent roles in the maintenance of cellular differentiation and induction of cell-cycle arrest and apoptosis. During early tumorigenesis, many tumour types lose responsiveness to TGF-β through biallelic loss-of-function mutations in genes that encode the TGF-β receptors or intracellular mediators of signalling (ref. 4 and references therein). Attenuation or loss of tumour responsiveness to TGF-β leads to increased signalling by the neighbouring signalling-competent stroma, owing to increased TGF-β ligand expression (Fig. 3b) . Consequences include impaired tumour surveillance owing to inhibition of adaptive immunity, acceleration of tumour growth because of enhanced angiogenesis, tumour invasion and metastasis, enhancement of innate immunity (mediated, at least in part, through MCP-1) and/or stimulation of epithelial-to-mesenchymal transition. TGF-β signalling can be further amplified in the tumour microenvironment through enhanced ligand expression by recruited inflammatory cells or enhanced TGF-β activation as a consequence of increased expression of activators such as MMPs. This sequence of events is not simply a function of the cell types per se, but more crucially the interface between cell types with a mismatch in their intrinsic capacity to support TGF-β signalling 50 . Could the cancer paradox inform the pathogenesis of aneurysm? The first potential link comes from a consideration of cellular ontology in the vascular system. VSMCs at the base of the aorta and pulmonary artery are derived from specialized cardiogenic mesoderm termed the second heart field (Fig. 3c) , a finding with possible implications for MFS 51 . The ascending aorta is a chimaera between cells derived from the second heart field and the ectodermal cardiac neural crest (CNC), whereas the CNC is the sole origin of VSMCs in the more distal ascending aorta and the transverse arch. There is an abrupt transition to somatic mesoderm-derived cells in the proximal descending thoracic (juxtaductal) aorta and a contribution of splanchnic mesoderm to the descending aorta beginning just below the diaphragm 52 . Thus, although there is not a common origin for VSMCs at frequent sites of predisposition for aneurysm, an interaction between cells of divergent origin exists at each location. Lineage-specific differences in intrinsic TGF-β signalling capacity were addressed in a study comparing the performance of ectoderm-derived cells from the aortic arch and mesoderm-derived cells from the abdominal aorta of chick embryos 53 .
After stimulation with TGF-β1, ectoderm-derived VSMCs showed increased DNA synthesis and robust transcriptional activation of a TGF-β reporter allele, whereas mesoderm-derived VSMCs showed little reporter activation and growth inhibition. TGF-β responsiveness correlated with differences in the glycosylation status of TGFR-2. The authors concluded that different SMC populations within a common vessel wall respond in lineage-dependent ways to growth factors that govern developmental events and that might participate in vascular disease in later life 53 . It seems plausible that cells of one lineage, such as mesodermal cells in the aortic root and descending thoracic aorta, would be more sensitive to a perturbation of TGF-β signalling. For example, this could be caused by a failure to concentrate cytokine in the setting of fibrillin-1 deficiency or by altered signalling capacity owing to heterozygous loss-of-function TGF-β receptor mutations. Loss of TGF-β feedback would initiate compensatory events such as increased TGF-β ligand expression, which could, in turn, stimulate neighbouring cells that can tolerate the primary insult better owing to improved reserves in their inherent signalling capacity (such as CNC-derived VSMCs). Indeed, inspection of the aortic wall from aneurysm tissue obtained at surgery shows an apparent binary status of medial VSMCs for TGF-β signalling (as determined by staining for nuclear pSMAD2), with neighbouring cells showing either strong or absent activity (Fig. 4) . Such a model not only accommodates but also mandates a mechanism for impaired TGF-β signalling, and would explain how compensatory events could lead to functional overshoot. It would also explain why aneurysms occur at the margins of the CNC developmental field, but not typically in its middle (Figs 1 and 3c) . In such a model, manipulations that limit TGF-β ligand bioavailability or block terminal pathogenetic events would be effective at preventing aneurysm, whereas those that accentuate the signalling imbalance would prove detrimental. Despite challenges, the effort to refine mechanistic understanding is justified by the high probability that these insights will yield treatment strategies for aneurysms and perhaps other clinical states associated with impaired vessel wall homeostasis. ■
